Baltimore, MD, February 08, 2018 --(PR.com
)-- Recognized internationally as leader in the field of immunotherapy, Dr. Julie R. Brahmer offers valuable insight in her role as the Director of the Thoracic Oncology Program and Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview. Headquartered in Baltimore, Maryland, Johns Hopkins Medicine (JHM) is the United States leading healthcare system focused on improving the health of the community and the world through means of research, clinical care, and medical education. JHM prides itself in transforming the future of healthcare and foster hope.
As the Director of the Thoracic Oncology Program and Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dr. Brahmer day-to-day responsibilities include clinical care, academic duties, and research tackling medical oncology and lung cancer. She directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and serves as a co-principal investigator on Johns Hopkins' National Clinical Trials Network.
In 1993, Dr. Brahmer earned her medical degree from the University of Nebraska Medical Center. To further her professional developments, she completed her residency at The University of Utah as the Chief Medical Resident in 1997 and fellowship at Johns Hopkins University School of Medicine in 2000. She is American Board Certified in Medical Oncology.
Dr. Brahmer maintains affiliation with the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee, American Association for Cancer Research, and International Association for the Study of Lung Cancer (IASLC). Additionally, she is a Founding Board Member for the National Lung Cancer Partnership, now known as Free to Breathe, and serves on the Medical Advisory Board of the Lung Cancer Research Fund and LUNGevity.
Due to her outstanding career and commitment to the field of Medicine, Dr. Brahmer is recognized as the Pinnacle Professional by Continental Who’s Who.
Dr. Brahmer became inspired to pursue the field of medicine through her grandfather’s lymphoma diagnosis. Her specialty covers analyzing the early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies.